Robert Liptak
CIK 1252523 · last filed 2019-02-11
Robert Liptak is a corporate insider who has filed 15 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for GMED, was dated Feb 11, 2019. Across all open-market trades the lifetime net is −$31.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.1M across reported positions. 58 SEC filings were submitted jointly with Dennis Henner.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AVNR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 CLARENDON STREET, 54TH FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GMED | Director | 41,159 | $75.90 | $3.12M | -$9.88M | 12 | 2019-02-11 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | 10%+ Owner | 3,522,879 | $15.25 | $53.72M | -$2.43M | 1 | 2014-12-30 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 1,185,305 | $26.68 | $31.62M | $7.00M | 1 | 2011-09-20 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | 10%+ Owner | 13,415,533 | — | — | -$26.29M | 1 | 2010-11-02 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-02-11 | GMED | Grant (A) | — | $0 | EDGAR |
| 2018-01-24 | GMED | Grant (A) | — | $0 | EDGAR |
| 2017-02-01 | GMED | Grant (A) | — | $0 | EDGAR |
| 2016-01-27 | GMED | Grant (A) | — | $0 | EDGAR |
| 2016-01-06 | GMED | Mixed | — | -$186.0K | EDGAR |
| 2015-01-22 | GMED | Grant (A) | — | $0 | EDGAR |
| 2014-12-30 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Sell (S) | −80,724 | -$2.43M | EDGAR |
| 2014-01-27 | GMED | Grant (A) | — | $0 | EDGAR |
| 2013-12-10 | GMED | Sell (S) | −25,000 | -$484.0K | EDGAR |
| 2013-09-05 | GMED | Other (J) | −7,193,042 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.